ASCO 2021: novelties in the field of lung cancer therapy analyzed by GECP specialists
allautoe 0 GECP congresses news
Between the 4th and the 8th of June, what is considered the main event in the field of Oncology, the Annual Meeting of the American Society of Clinical Oncology (ASCO 2021) took place. Given the high amount of news and advances presented, News Farma invited three representatives of the Lung Cancer Study Group (GECP) – Dr. Teresa Almodovar, Dr. Carina Gaspar and Dr. Ana Rodrigues – to attend highlight some of the published studies and works that will make a difference in the treatment of lung cancer.
Dr. Teresa Almodovar, pulmonologist at the Portuguese Oncology Institute of Lisbon (IPO Lisbon) and president of the GECP, selected the studies presented during ASCO 2021 which, in her view, could be “future indications to change therapeutic decisions in cancer of the lung at early stages”. The VIOLET and STARS studies in the field of local therapy, the IMPACT study and the EMERGING-CTONG 1103 clinical trial in the area of target therapy and the IMpower010, CheckMate 816 and PACIFIC studies in the field of immunotherapy, were the works highlighted by the specialist, whose full interview can be viewed at https://bit.ly/35GusHR.
In her turn, Dr. Carina Gaspar, pulmonologist at the Portuguese Institute of Oncology of Lisbon (IPO Lisbon), highlighted some works focused on advanced non-small cell lung cancer (NSCLC) with driver mutations, “one of the areas with the greatest innovation in recent years”. During her video statement (https://bit.ly/3qixbAB), the most relevant data in the area of target therapies for advanced NSCLC with EGFR mutation previously treated with insert tyrosine kinase (TKI) inhibitors were highlighted of exon 20 of EGFR, with mutation KRAS p.G12C and mutation of exon 14 of MET, which the specialist hopes “may translate within a short time into more therapeutic options for patients”.
Finally, Dr. Ana Rodrigues, an oncologist at the Portuguese Institute of Oncology of Porto (IPO Porto), was also challenged by News Farma to mention the studies in the area of immunotherapy for the CPNPC that stood out in this year’s Annual Meeting. of ASCO. Nivolumab and ipilimumab in the 1st-line treatment of patients with advanced NSCLC without target mutations, the immune-mediated adverse effects associated with immunotherapy and survival, the impact of the microbiome on the response to immunotherapy and the combination of immunotherapy and chemotherapy in the treatment in 1. The first line of tumors with a PD-L1 score of 1-49% were the focus of the studies referred to by the specialist, whose statements were also recorded on video and can be consulted at: https://bit.ly/3xIIC76.